HRI researchers take steps to prevent peripheral artery disease
HRI’s Arterial Inflammation and Redox Biology Group has made an important discovery in preventing peripheral artery disease.
HRI expands research into inflammation and blood pressure disorders
HRI is delighted to welcome Dr Christopher Stanley as lead of the Microvascular Research Group.
Global media interest in HRI’s breakthrough anti-clotting drug for COVID-19
The revolutionary new anti-clotting medicine developed by HRI has attracted global media interest due to its far-reaching impact.
Collaboration advancing medical research: Drs Anna Waterhouse and John O’Sullivan
Collaboration is essential to advancing medical research, so HRI are delighted that Drs Anna Waterhouse and John O’Sullivan and their multiple research collaborations are featured by the Charles Perkins Centre, The University of Sydney.
HRI Director of Cardiovascular Research in the UK
HRI’s Director of Cardiovascular Research, Professor Shaun Jackson, recently travelled to the UK to hold discussions with scientific and clinical colleagues in the UK as well as members of the British Heart Foundation (BHF) about the global state of cardiovascular disease, its impact on the community, and how we can best fight it.
International collaboration to detect AF through face scans
HRI has worked on new camera technology that can detect deadly heart problems by scanning patients' faces in a GP waiting room.
HRI UK funds cutting-edge microscopes
The generosity of HRI UK supporters has enabled the purchase of two cutting-edge microscopes that will help speed our cardiovascular disease research to the next breakthrough.
Heart disease research in the UK
Professor Willem Ouwehand, Professor of Experimental Haematology at the University of Cambridge and at the Sanger Institute speaks to Professor Ben Freedman, Deputy Director Research Strategy and Group Leader at HRI about the state of heart disease research in the UK and the potential for research collaborations.
Dr John O’Sullivan awarded prestigious grant
Originally from Ireland, Dr John O’Sullivan has been awarded a grant under the NSW Government’s transformative $150 million investment in cardiovascular research.